ACTL10

Across TCGA pan-cancer cohorts, ACTL10 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ACTL10 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ACTL10 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ACTL10 expression acts as an unfavorable survival marker.

COAD, SCLC, and BLCA are the cancer types where ACTL10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.001	0.871	<.001	24	view →
SCLC	DFS	Median	II,III,IV	0.137	0.602	.008	15	view →
BLCA	DFS	Median	All	0.100	0.626	<.001	12	view →
ESCA	DFS	Median	II,III,IV	0.082	0.523	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ACTL10–COAD (OS)

Open the COAD breakdown →